Clinuvel Pharmaceuticals Limited Stock OTC Markets
Stocks
CLVLY
US1887691038
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.300 USD | +1.39% |
|
+2.82% | -13.92% |
| 06-16 | Clinuvel Pharmaceuticals Advances US Listing Plan With SEC Filing for Nasdaq ADS Upgrade | MT |
| 04-28 | Clinuvel Pharmaceuticals plans level II ADR upgrade and Nasdaq listing as CUVL | RE |
| Market Cap | 518M 359M 314M 290M 270M 509M 33.91B 3.48B 1.35B 16.73B 1.35B 1.32B 58.29B | P/E 2026 * |
14.4x | P/E 2027 * | 13.6x |
|---|---|---|---|---|---|
| Enterprise Value | 265M 183M 160M 148M 138M 260M 17.31B 1.77B 689M 8.54B 688M 673M 29.77B | EV / Sales 2026 * |
2.66x | EV / Sales 2027 * | 2.21x |
| Free-Float |
83.79% | Yield 2026 * |
0.59% | Yield 2027 * | 0.78% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | +1.39% | ||
| 1 week | +2.82% | ||
| 1 month | +9.36% | ||
| 3 months | +0.83% | ||
| 6 months | -13.92% | ||
| Current year | -13.92% |
| 1 week | 6.65 |  | 7.67 |
| 1 month | 6.19 | | 7.67 |
| Current year | 5.98 | | 8.67 |
| 1 year | 5.98 | | 9 |
| 3 years | 5.98 | | 13.55 |
| 5 years | 5.98 | | 31.44 |
| 10 years | 3.25 | | 31.44 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.39% | +2.82% | - | - | 359M | |
| -1.31% | +0.89% | +18.77% | -13.22% | 63.44B | |
| -0.57% | +4.09% | +56.93% | +222.66% | 56.98B | |
| -3.94% | +39.10% | +39.10% | +39.10% | 41.58B | |
| +2.95% | +2.74% | -50.41% | -57.23% | 38.01B | |
| -0.26% | +9.57% | +72.04% | -24.15% | 31.9B | |
| +0.47% | +14.80% | +153.82% | -42.36% | 27.79B | |
| -1.13% | +8.58% | +66.46% | +82.10% | 22.65B | |
| -0.56% | +4.05% | +1.53% | +168.92% | 17.64B | |
| -0.13% | -0.94% | +60.31% | +119.58% | 16.49B | |
| Average | -0.31% | +5.10% | +46.51% | +55.04% | 35.16B | |
| Weighted average by Cap. | -0.63% | +4.46% | +41.84% | +51.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.46M 68.81M 60.23M 55.6M 51.86M 97.71M 6.51B 667M 259M 3.21B 259M 253M 11.18B | 105M 72.88M 63.8M 58.89M 54.93M 104M 6.89B 706M 274M 3.4B 274M 268M 11.85B |
| Net income | 35.97M 24.88M 21.78M 20.1M 18.75M 35.33M 2.35B 241M 93.62M 1.16B 93.48M 91.39M 4.04B | 38.2M 26.43M 23.13M 21.35M 19.92M 37.53M 2.5B 256M 99.44M 1.23B 99.29M 97.07M 4.3B |
| Net Debt | -254M -176M -154M -142M -132M -249M -16.59B -1.7B -660M -8.19B -659M -645M -28.53B | -286M -198M -173M -160M -149M -281M -18.71B -1.92B -745M -9.23B -743M -727M -32.16B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/06/26 | $7.300 | +1.39% | 2,158 |
| 29/06/26 | $7.200 | +2.16% | 8,804 |
| 25/06/26 | $7.048 | -0.73% | 9,682 |
| 24/06/26 | $7.100 | -.--% | 1,200 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
- CLVLY Stock
Select your edition
All financial news and data tailored to specific country editions
